CAS: 1109276-89-2; 2-(Trans-4-(4-(4-Amino-5-Oxo-7,8-Dihydropyrimido[5,4-F][1,4]Oxazepin-6(5H)-yl)Phenyl)Cyclohexyl)Acetic Acid

结构式图片

欧盟法规

C&L通报

上下游产品

methyl {trans-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-(5H)-yl)phenyl]cyclohexyl}acetate2-{trans-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexyl}-N-(methylsulfonyl)acetamide 4-amino-6-{4-[trans-4-(2-oxo-2-pyrrolidin-1-ylethyl)cyclohexyl]phenyl}-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one trans-N-acetyl-N'-(2-{4-[4-(4-amino-5-oxo-7,8-dihydro-5H-9-oxa-1,3,6-triazabenz°Cyclohepten-6-yl)phenyl]cyclohexyl}acetyl)hydrazine trans-2-{4-[4-(4-amino-5-oxo-7,8-dihydro-5H-9-oxa-1,3,6-triazabenz°Cyclohepten-6-yl)phenyl]cyclohexyl}-N-methylacetamide

合成工艺路线路线简述

    📜Cyclohexaneacetic Acid,4-[4-(4-Amino-7,8-Dihydro-5-Oxopyrimido[5,4-F][1,4]Oxazepin-6(5H)-yl)Phenyl]-,Methyl Ester,Trans-以94.8的收率获得pf-04620110; 反式-4-[4-(4-氨基-7,8-二氢-5-氧代嘧啶并[5,4-F][1,4]氧氮杂卓-6(5H)-基)苯基]环己烷乙酸
    参考文献:Acs Med. Chem. Lett. 2011,2,407-412
    标题:Acs Med. Chem. Lett. 2011,2,407-412

    海关参考信息

    专利信息


    专利号:US-12016933-B2
    优先权日:2020-11-25
    标题:Method for stimulating axonal regeneration
    发明人:YANG CHAO; WANG XU; LIU KAI
    权利人:UNIV HONG KONG SCIENCE & TECH
    摘要:A method of promoting axonal regeneration can include directing neuronal lipid synthesis away from triglyceride synthesis and toward phospholipid synthesis. The method can include administering to the patient a therapeutically effective amount of an inhibitor compound selected from the group consisting of a Lipin-1 inhibitor, a diglyceride acyltransferase inhibitor, and combinations thereof or administering a gene editing therapy to the patient that reduces expression of LIPIN1 or a diglyceride acyltransferase gene.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Amin NB, Saxena AR, Somayaji V, Dullea R. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase
    1: Potential Therapeutic Implications of Pharmacology. Clin Ther. 2023 Jan;45(1):55-70. doi: 10.1016/j.clinthera.2022.12.008. Epub 2023 Jan 21. 8(15):e14542. doi: 10.14814/phy2.14542.
    3: Jo SI, Bae JH, Kim SJ, Lee JM, Jeong JH, Moon JS. PF-04620110, a Potent Antidiabetic Agent, Suppresses Fatty Acid-Induced NLRP3 Inflammasome Activation in Macrophages. Diabetes Metab J. 2019 Oct;43(5):683-699. doi: 10.4093/dmj.2019.0112.

    合成参考文献


    参考文献:10.1021/ml200051p
    摘要:Dow RL, Li JC, Pence MP, Gibbs EM, LaPerle JL, Litchfield J, Piotrowski DW, Munchhof MJ, Manion TB, Zavadoski WJ, Walker GS, McPherson RK, Tapley S, Sugarman E, Guzman-Perez A, DaSilva-Jardine P. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. ACS Med Chem Lett. 2011 May 12;2(5):407–12.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知